Lineage Cell Therapeutics, Inc. Marketable Securities (Current)
Lineage Cell Therapeutics, Inc. (LCTX) had Marketable Securities (Current) of $13.47 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $13.47M.
- 2026-03-31: Marketable Securities, Current $17.44M.
- 2025-12-31: Marketable Securities, Current $14.99M.
- 2025-09-30: Marketable Securities, Current $23.00K.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $13.47M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.44M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $14.99M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $19.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $2.02M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.96M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $8.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $45.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $50.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $9.86M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $12.04M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $31.36M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $46.52M 10-K · filed 2024-03-07 |
| 2022-09-30 | $41.60M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.17M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.88M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.62M 10-K · filed 2023-03-09 |
| 2021-09-30 | $4.29M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $6.75M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $6.15M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $8.98M 10-K · filed 2022-03-10 |
| 2020-09-30 | $5.48M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $7.58M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $15.93M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $21.22M 10-K · filed 2021-03-11 |
| 2019-09-30 | $21.32M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $8.48M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $9.09M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $7.15M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.97M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.95M 10-Q · filed 2018-08-02 |
| 2017-12-31 | $1.34M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |